Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line.
about
Mitogen-activated protein kinases in normal and (pre)neoplastic ovarian surface epitheliumCross-talk between signalling pathways and the multidrug resistant protein MDR-1DNA damage-induced G2/M checkpoint in SV40 large T antigen-immortalized embryonic fibroblast cells requires SHP-2 tyrosine phosphatasePleiotropic effects of PI-3' kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis.Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells.Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation.Cellular responses to Cisplatin-induced DNA damage.Cisplatin in cancer therapy: molecular mechanisms of actionLoss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer.Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.Control of oncogenesis and cancer therapy resistance.Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma.On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapyTetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers.Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatinCharacterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo.Targeting prostate cancer based on signal transduction and cell cycle pathways.Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.Alterations of microRNA expression patterns in human cervical carcinoma cells (Ca Ski) toward 1'S-1'-acetoxychavicol acetate and cisplatin.The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cellsResistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.Apoptotic and chemotherapeutic properties of iron (III)-salophene in an ovarian cancer animal model.Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.Inorganic phosphate enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin via a p53-dependent pathway.Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells.Cell proliferation, apoptosis and mitochondrial damage in rat B50 neuronal cells after cisplatin treatment.Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin.p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis.Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells.Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models.Downregulation of ERK2 is essential for the inhibition of radiation-induced cell death in HSP25 overexpressed L929 cells.Activation of the luteinizing hormone beta promoter by gonadotropin-releasing hormone requires c-Jun NH2-terminal protein kinase.MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps.Compartmentalized Ras signaling differentially contributes to phenotypic outputsCombined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress.VRK1 promotes cisplatin resistance by up-regulating c-MYC via c-Jun activation and serves as a therapeutic target in esophageal squamous cell carcinoma.
P2860
Q24805605-59685DC4-C129-4514-93AA-D27F13CCB8A2Q28364226-58B4771D-CDFC-4E88-A68A-B5AA215E1CD8Q28590697-52D61D79-5D1C-44BF-8243-7FEF31A22646Q33279919-44737CF2-A470-4615-9A2B-141C915B230FQ33710438-269E47EE-CDE2-42ED-B3C4-FA786C4B1C27Q33713850-3D0D7F5D-B042-4B0D-A95B-7104F6FFEB2BQ33938470-094ED529-A007-49EC-B642-AB549FA0959FQ34089685-018ED47A-99EF-4C38-9007-990232EF6BDAQ34098163-6FED29C4-53D0-493F-997C-958653547806Q34189632-C44DABFE-5432-4AE2-B81A-4DA03EED47CAQ34285363-5F1F0EEE-D580-4A37-973D-EFDE446809F6Q34973413-770A3D77-6A7A-4025-B529-81BD68FD5F47Q35647850-C071E6CA-2552-4D2B-B5C4-EA96906F46BEQ35800638-53FA2FE6-9211-48DA-95FC-452750F844ACQ36107216-66A6C997-A14D-4852-A2F0-AC946A4F328DQ36280333-DBFD6138-9566-40F9-ADD0-EF9599C96949Q36580055-6A99A523-810B-4076-A5D6-AC97E023F3F8Q36695785-248E4A78-5664-49EA-A606-D422516467B5Q36995054-3C14EAA2-23D3-498E-9E8E-70C100F2FC55Q37000508-7754E370-48CB-419A-B708-FD7F7A22DF61Q37019591-27673824-2DD9-4C35-84DC-3144024C4B38Q37055940-7E915DD9-95E5-4C40-866E-4A7B319CB595Q37140728-577F8A66-CD2F-4231-B824-6D4303EF2193Q37403199-A8646220-0E0F-4CCC-B749-BDB3BDE132DDQ38846377-E95BD915-74C9-4E8F-A178-405F904C5E29Q39335691-1562FC07-9ADA-4BBC-8DEB-617A51C80EE9Q39400141-2A3FC694-9C1E-4C17-924A-5485F64347FDQ39839523-A26E7A09-4F77-4835-87D6-FB1F8DF8AD86Q39925551-91C4290B-5461-4C6A-96F8-90B5D0E37A16Q39993992-406BD8C8-B1A6-476A-8A62-86ACBEF96483Q40066545-8C14628C-439A-4221-A085-5CB4B29B8E4BQ40185793-9672FE0B-FF02-4822-8D01-AF47C0B29C25Q40249347-A163E0A3-DC89-4591-9D57-4F6A979257E9Q40577628-FA2691D1-8131-421D-814D-B3878BB11E2EQ40736876-D4F844B6-ED8E-4A5E-978C-50E91130DC18Q40883233-1165D153-5556-4155-BE7A-4BF46270F54EQ41078238-95DB4003-7D09-4641-97A9-01650292855AQ42146907-632C8FD7-4B6A-47AC-A7AE-31A4AE22F46EQ42204382-97687B14-0033-43F2-AB2C-6A4692945CE6Q42371566-39D17103-0EAE-49B5-B4F9-2836B8098388
P2860
Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Inhibition of extracellular si ...... uman ovarian cancer cell line.
@en
type
label
Inhibition of extracellular si ...... uman ovarian cancer cell line.
@en
prefLabel
Inhibition of extracellular si ...... uman ovarian cancer cell line.
@en
P2093
P2860
P356
P1476
Inhibition of extracellular si ...... uman ovarian cancer cell line.
@en
P2093
H Jikihara
J Hayakawa
T Matsuoka
P2860
P304
31648-31654
P356
10.1074/JBC.274.44.31648
P407
P577
1999-10-01T00:00:00Z